SPDR S&P Biotech ETF
427 hedge funds and large institutions have $4.42B invested in SPDR S&P Biotech ETF in 2018 Q4 according to their latest regulatory filings, with 92 funds opening new positions, 113 increasing their positions, 149 reducing their positions, and 91 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
427
Holders Change
-5
Holders Change %
-1.16%
% of All Funds
9.53%
Holding in Top 10
14
Holding in Top 10 Change
-6
Holding in Top 10 Change %
-30%
% of All Funds
0.31%
New
92
Increased
113
Reduced
149
Closed
91
Calls
$1.01B
Puts
$1.89B
Net Calls
-$876M
Net Calls Change
+$226M
Top Buyers
| 1 |
UBS Group
Zurich,
Switzerland
|
+$358M |
| 2 |
Citigroup
New York
|
+$165M |
| 3 |
Wells Fargo
San Francisco,
California
|
+$45.8M |
| 4 |
Jane Street
New York
|
+$44.5M |
| 5 |
Morgan Stanley
New York
|
+$25.2M |
Top Sellers
| 1 |
Goldman Sachs
New York
|
-$160M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$132M |
| 3 |
BNP Paribas Financial Markets
Paris,
France
|
-$82.9M |
| 4 |
AllianceBernstein
Nashville,
Tennessee
|
-$58.5M |
| 5 |
AssetMark Inc
Concord,
California
|
-$58.4M |
